Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (41-50 of 318) with videos related to

Pageof 32
Sort By:
Intervirology|April 18, 2009
An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loadsHitomi Sezaki, Fumitaka Suzuki, Norio Akuta, et al.
The American Journal of Medicine|October 31, 2006
Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferaseKenji Ikeda, Yasuji Arase, Satoshi Saitoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2007
Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral loadHitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, et al.
Journal of Gastroenterology|October 14, 2023
Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearanceFumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, et al.
Oncology|April 14, 2026
Serum microRNA-122 predicts early progressive disease in unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab therapyShigeki Yamamoto, Norio Akuta, Tetsuya Hosaka, et al.
Journal of Gastroenterology|September 1, 2004
Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatmentSatoshi Mamori, Fumitaka Suzuki, Tetsuya Hosaka, et al.
Journal of Gastroenterology|December 8, 2004
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis CYasuji Arase, Kenji Ikeda, Fumitaka Suzuki, et al.
Internal Medicine (Tokyo, Japan)|March 4, 2008
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus loadYusuke Kawamura, Yasuji Arase, Kenji Ikeda, et al.
Journal of Medical Virology|February 17, 2006
Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infectionsMasahiro Kobayashi, Kenji Ikeda, Tetsuya Hosaka, et al.
Journal of Gastroenterology|December 25, 2008
Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patientsHiromi Saneto, Masahiro Kobayashi, Yusuke Kawamura, et al.
Pageof 32

Showing results (41-50 of 318) with videos related to

Sort By:
Pageof 32
Intervirology|April 18, 2009
An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loadsHitomi Sezaki, Fumitaka Suzuki, Norio Akuta, et al.
The American Journal of Medicine|October 31, 2006
Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferaseKenji Ikeda, Yasuji Arase, Satoshi Saitoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2007
Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral loadHitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, et al.
Journal of Gastroenterology|October 14, 2023
Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearanceFumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, et al.
Oncology|April 14, 2026
Serum microRNA-122 predicts early progressive disease in unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab therapyShigeki Yamamoto, Norio Akuta, Tetsuya Hosaka, et al.
Journal of Gastroenterology|September 1, 2004
Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatmentSatoshi Mamori, Fumitaka Suzuki, Tetsuya Hosaka, et al.
Journal of Gastroenterology|December 8, 2004
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis CYasuji Arase, Kenji Ikeda, Fumitaka Suzuki, et al.
Internal Medicine (Tokyo, Japan)|March 4, 2008
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus loadYusuke Kawamura, Yasuji Arase, Kenji Ikeda, et al.
Journal of Medical Virology|February 17, 2006
Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infectionsMasahiro Kobayashi, Kenji Ikeda, Tetsuya Hosaka, et al.
Journal of Gastroenterology|December 25, 2008
Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patientsHiromi Saneto, Masahiro Kobayashi, Yusuke Kawamura, et al.
Pageof 32